Iranian Journal of Pathology

Investigation of Non-Coding RNA-Related Autophagy Alterations in Drug-Resistant Multiple Myeloma Plasma Cells

Document Type : Original Research

Authors

Leila Sarafraznia 1
Zari Tahan Nejad Asadi 1, 2
Dian Dayer 3
Mohammad Ali Jalali Far 1, 2
Nariman Ghanatir 2

1 Department of Laboratory Sciences, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Thalassemia & Hemoglobinopathy Research center, Health research institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3 Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

https://doi.org/10.30699/ijp.2024.2022061.3256
Abstract
Background & Objective: Multiple myeloma (MM) drug resistance is thought to be caused by the development of protective autophagy. This work aimed to assess the non-coding RNA (ncRNA) autophagy-related alterations in drug-resistant (DR) myeloma cells.
Methods: DR Plasma cells were extracted from the bone marrow of DR patients referred to Baghai 2 Hospital in Ahvaz, Iran. The cells were grown in RPMI-1640 media containing 10% FBS and 1% Pen/Strep and incubated at 37˚C and 5% CO2. After six passages, the plasma cells were precisely isolated and utilized as DR cells. The U266B1 cell line (IBRC C10148) was grown in the RPMI-1640 media containing 10% FBS and 1% Pen/Strep and utilized as drug-sensitive (DS) cells. The relative expression of the genes was determined using the Real-time PCR method. Statistical analysis of the data was performed using GraphPad Prism 8 software.  
Results: When the DR cells were compared to the DS cells, there was a notable increase in the expression of ULK1 and LC3B. However, expression of P62 in the DR plasma cells showed a significant decrease compared to the DS plasma cells. The miR-1297 level was considerably higher in the DR cells than in the DS cells. Although, there was no statistically significant difference in the expression of miR-26a-5p between the DS and DR cells. The DR cells exhibited a statistically significant increase in the expression of MALAT1 and SNHG6.
Conclusion: Drug resistance in MM cells may result from overexpression of non-coding RNAs involved in autophagy.

Keywords

Multiple myeloma
Drug resistance
Autophagy
non-coding RNA
Plasma cell

Subjects

  1. Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, et al. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel). 2021;9(1):3. [DOI:10.3390/medsci9010003] [PMID] [PMCID]
  2. Bauer K, Rancea M, Schmidtke B, Kluge S, Monsef I, Hubel K, et al. Thirteenth biannual report of the Cochrane Haematological Malignancies Group--focus on multiple myeloma. J Natl Cancer Inst. 2011;103(17):E1-19. [DOI:10.1093/jnci/djr271] [PMID]
  3. Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol. 2022;33(3):259-75. [DOI:10.1016/j.annonc.2021.12.003] [PMID]
  4. Papadas A, Asimakopoulos F. Mechanisms of Resistance in Multiple Myeloma. Handb Exp Pharmacol. 2018;249:251-88. [DOI:10.1007/164_2017_10] [PMID]
  5. Op M, Ribeiro ST, Chavarria C, De Gassart A, Zaffalon L, Martinon F. The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma. Cell Death Dis. 2022;13(5):475. [DOI:10.1038/s41419-022-04925-3] [PMID] [PMCID]
  6. Habič A, Novak M, Majc B, Lah Turnšek T, Breznik BJJoH, Cytochemistry. Proteases regulate cancer stem cell properties and remodel their microenvironment. 2021;69(12):775-94.PMID] [PMCID] [DOI:10.1369/00221554211035192] [
  7. Kaur G, Gupta SK, Singh P, Ali V, Kumar V, Verma M. Drug-metabolizing enzymes: role in drug resistance in cancer. Clin Transl Oncol. 2020;22(10):1667-80. [DOI:10.1007/s12094-020-02325-7] [PMID]
  8. Engle K, Kumar G. Tackling multi-drug resistant fungi by efflux pump inhibitors. Biochem Pharmacol. 2024;226:116400. [DOI:10.1016/j.bcp.2024.116400] [PMID]
  9. Ito S. Proteasome Inhibitors for the Treatment of Multiple Myeloma. Cancers (Basel). 2020;12(2):265. [DOI:10.3390/cancers12020265] [PMID] [PMCID]
  10. Meul T, Berschneider K, Schmitt S, Mayr CH, Mattner LF, Schiller HB, et al. Mitochondrial Regulation of the 26S Proteasome. Cell Rep. 2020;32(8):108059. [DOI:10.1016/j.celrep.2020.108059] [PMID]
  11. Bai Y, Su X. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma. Asia Pac J Clin Oncol. 2021;17(1):29-35. [DOI:10.1111/ajco.13459] [PMID]
  12. Pinto V, Bergantim R, Caires HR, Seca H, Guimaraes JE, Vasconcelos MH. Multiple Myeloma: Available Therapies and Causes of Drug Resistance. Cancers (Basel). 2020;12(2):407. [DOI:10.3390/cancers12020407] [PMID] [PMCID]
  13. Jiang W, Xia J, Xie S, Zou R, Pan S, Wang Z-w, et al. Long non-coding RNAs as a determinant of cancer drug resistance: Towards the overcoming of chemoresistance via modulation of lncRNAs. 2020;50:100683. [DOI:10.1016/j.drup.2020.100683] [PMID]
  14. Li D, Zhang J, Li J. Role of miRNA sponges in hepatocellular carcinoma. Clin Chim Acta. 2020;500:10-9. [DOI:10.1016/j.cca.2019.09.013] [PMID]
  15. Papoutsoglou P, Moustakas A. Long non-coding RNAs and TGF-beta signaling in cancer. Cancer Sci. 2020;111(8):2672-81. [DOI:10.1111/cas.14509] [PMID] [PMCID]
  16. Chang H, Zou ZJJoh, oncology. Targeting autophagy to overcome drug resistance: further developments. 2020;13(1):159. [DOI:10.1186/s13045-020-01000-2] [PMID] [PMCID]
  17. Al-Hawary SIS, Jasim SA, Altalbawy FMA, Hjazi A, Jyothi SR, Kumar A, et al. Highlighting the role of long non-coding RNA (LncRNA) in multiple myeloma (MM) pathogenesis and response to therapy. Med Oncol. 2024;41(7):171. [DOI:10.1007/s12032-024-02392-8] [PMID]
  18. Liu X, Chen Q, Jiang S, Shan H, Yu T. MicroRNA-26a in respiratory diseases: mechanisms and therapeutic potential. Mol Biol Rep. 2024;51(1):627. [DOI:10.1007/s11033-024-09576-5] [PMID]
  19. Liu X, Wang H, Yang M, Hou Y, Chen Y, Bie P. Exosomal miR-29b from cancer-associated fibroblasts inhibits the migration and invasion of hepatocellular carcinoma cells. Transl Cancer Res. 2020;9(4):2576-87. [DOI:10.21037/tcr.2020.02.68] [PMID] [PMCID]
  20. Zhu J, Wang L. The Role of lncRNA-miR-26a-mRNA Network in Cancer Progression and Treatment. Biochem Genet. 2024;62(3):1443-61. [DOI:10.1007/s10528-023-10475-w] [PMID]
  21. Li Y, Li S, Wu H. Ubiquitination-Proteasome System (UPS) and Autophagy Two Main Protein Degradation Machineries in Response to Cell Stress. Cells. 2022;11(5):851. [DOI:10.3390/cells11050851] [PMID] [PMCID]
  22. Zhou X, He R, Hu W-X, Luo S, Hu JJN. Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors. 2024;50:100974. [DOI:10.1016/j.neo.2024.100974] [PMID] [PMCID]
  23. Di Lernia G, Leone P, Solimando AG, Buonavoglia A, Saltarella I, Ria R, et al. Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. J Clin Med. 2020;9(2):552. [DOI:10.3390/jcm9020552] [PMID] [PMCID]
  24. Pu Y, Wang J, Wang S. Role of autophagy in drug resistance and regulation of osteosarcoma (Review). Mol Clin Oncol. 2022;16(3):72. [DOI:10.3892/mco.2022.2505] [PMID] [PMCID]
  25. Desantis V, Saltarella I, Lamanuzzi A, Mariggio MA, Racanelli V, Vacca A, et al. Autophagy: A New Mechanism of Prosurvival and Drug Resistance in Multiple Myeloma. Transl Oncol. 2018;11(6):1350-7. [DOI:10.1016/j.tranon.2018.08.014] [PMID] [PMCID]
  26. Duran GAJJoE, Medicine C. Circulating tumour cells differentially express upregulated cancer biomarkers "lncRNAs and miRNAs" compared to bone marrow biopsy samples in multiple myeloma patients. 2024;41(2):351-60.
  27. Moftakhar A, Najafi S, Anbiyaee O, Farzaneh M, Khoshnam SEJCCTR. Functional Roles of the lncRNA MALAT1 in Glioma. 2024;20(2):166-76. [DOI:10.2174/1573394719666230720164009]
  28. Piorkowska K, Zygmunt K, Hunter W, Wroblewska K. MALAT1: A Long Non-Coding RNA with Multiple Functions and Its Role in Processes Associated with Fat Deposition. Genes (Basel). 2024;15(4):479. [DOI:10.3390/genes15040479] [PMID] [PMCID]
  29. Hjazi A, Jasim SA, Altalbawy FM, Kaur H, Hamzah HF, Kaur I, et al. Relationship between lncRNA MALAT1 and Chemo-radiotherapy Resistance of Cancer Cells: Uncovered Truths. 2024:1-15. [DOI:10.1007/s12013-024-01317-6] [PMID]
  30. Ghafouri-Fard S, Abak A, Tondro Anamag F, Shoorei H, Majidpoor J, Taheri M. The emerging role of non-coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process. Biomed Pharmacother. 2021;137:111279. [DOI:10.1016/j.biopha.2021.111279] [PMID]
  31. Mei J, Liu G, Li R, Xiao P, Yang D, Bai H, et al. LncRNA SNHG6 knockdown inhibits cisplatin resistance and progression of gastric cancer through miR-1297/BCL-2 axis. 2021;41(12):BSR20211885. [DOI:10.1042/BSR20211885] [PMID] [PMCID]
  32. Jurkiewicz M, Szczepaniak A, Zielińska MJBeBA-RoC. Long non-coding RNAs-SNHG6 emerge as potential marker in colorectal cancer. 2023:189056. [DOI:10.1016/j.bbcan.2023.189056] [PMID]
  33. Chen E, Li E, Liu H, Zhou Y, Wen L, Wang J, et al. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy. Int J Biol Sci. 2021;17(3):781-95. [DOI:10.7150/ijbs.52517] [PMID] [PMCID]
  34. Yang N-Q, Luo X-J, Zhang J, Wang G-M, Guo J-MJAjotr. Crosstalk between Meg3 and miR-1297 regulates growth of testicular germ cell tumor through PTEN/PI3K/AKT pathway. 2016;8(2):1091.
  35. Chen M, Jiang J, Hou JJBR. Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications. 2023;11(1):55. [DOI:10.1186/s40364-023-00502-8] [PMID] [PMCID]
  36. Wang C, Wang W, Wang M, Deng J, Sun C, Hu Y, et al. Different evasion strategies in multiple myeloma. Front Immunol. 2024;15:1346211.[PMCID] [DOI:10.3389/fimmu.2024.1346211] [PMID]
  37. Karimi Kelaye S, Najafi F, Kazemi B, Foruzandeh Z, Seif F, Solali S, et al. The contributing factors of resistance or sensitivity to epigenetic drugs in the treatment of AML. Clin Transl Oncol. 2022;24(7):1250-61. [DOI:10.1007/s12094-022-02776-0] [PMID]
  38. Khouri J, Faiman BM, Grabowski D, Mahfouz RZ, Khan SN, Wei W, et al., editors. DNA methylation inhibition in myeloma: experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Seminars in Hematology; 2021: Elsevier. [DOI:10.1053/j.seminhematol.2020.12.004] [PMID]
  39. Das D, Karthik N, Taneja RJFiC, Biology D. Crosstalk between inflammatory signaling and methylation in cancer. 2021;9:756458. [DOI:10.3389/fcell.2021.756458] [PMID] [PMCID]
  40. Rascio F, Spadaccino F, Rocchetti MT, Castellano G, Stallone G, Netti GS, et al. The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review. Cancers (Basel). 2021;13(16):3949. [DOI:10.3390/cancers13163949] [PMID] [PMCID]
  41. Ho M, Goh CY, Patel A, Staunton S, O'Connor R, Godeau M, et al. Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. Clin Lymphoma Myeloma Leuk. 2020;20(10):e752-e68. [DOI:10.1016/j.clml.2020.05.026] [PMID]
  42. Bhowmick K, von Suskil M, Al-Odat OS, Elbezanti WO, Jonnalagadda SC, Budak-Alpdogan T, et al. Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells. Heliyon. 2024;10(12):e33091. [DOI:10.1016/j.heliyon.2024.e33091] [PMID] [PMCID]
  43. Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Farahani MV, Hushmandi K, et al. Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discov Today. 2022;27(2):436-55. [DOI:10.1016/j.drudis.2021.09.020] [PMID]
  44. Kozalak G, Butun I, Toyran E, Kosar A. Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies. Pharmaceuticals (Basel). 2023;16(1):111. [DOI:10.3390/ph16010111] [PMID] [PMCID]
  45. Wu H, Liu C, Yang Q, Xin C, Du J, Sun F, et al. MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4. Autophagy. 2020;16(4):683-97. [DOI:10.1080/15548627.2019.1635380] [PMID] [PMCID]
  46. Jiang L, Zhao YM, Yang MZ. Inhibition of autophagy enhances apoptosis induced by bortezomib in AML cells. Oncol Lett. 2021;21(2):109. [DOI:10.3892/ol.2020.12370] [PMID] [PMCID]
  47. Bashiri H, Tabatabaeian H. Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma. Int J Mol Sci. 2023;24(7):6019. [DOI:10.3390/ijms24076019] [PMID] [PMCID]
  48. Zhu C, Song Z, Wang A, Srinivasan S, Yang G, Greco R, et al. Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells. 2020;11:1771. [DOI:10.3389/fimmu.2020.01771] [PMID] [PMCID]
  49. Ndacayisaba LJ, Rappard KE, Shishido SN, Ruiz Velasco C, Matsumoto N, Navarez R, et al. Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones. Curr Oncol. 2022;29(5):2954-72. [DOI:10.3390/curroncol29050242] [PMID] [PMCID]
  50. Tang X, Luo X, Wang X, Zhang Y, Xie J, Niu X, et al. Chrysin Inhibits TAMs-Mediated Autophagy Activation via CDK1/ULK1 Pathway and Reverses TAMs-Mediated Growth-Promoting Effects in Non-Small Cell Lung Cancer. Pharmaceuticals (Basel). 2024;17(4):515. [DOI:10.3390/ph17040515] [PMID] [PMCID]
  51. Bhattacharya S, Piya S, Ma H, Sharma P, Zhang Q, Baran N, et al. Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia. Mol Cancer Res. 2023;21(6):548-63.[PMCID] [DOI:10.1158/1541-7786.MCR-22-0343] [PMID]
  52. Noguchi M, Hirata N, Tanaka T, Suizu F, Nakajima H, Chiorini JAJCd, et al. Autophagy as a modulator of cell death machinery. 2020;11(7):517. [DOI:10.1038/s41419-020-2724-5] [PMID] []
  53. Yamamoto H, Zhang S, Mizushima N. Autophagy genes in biology and disease. Nat Rev Genet. 2023;24(6):382-400. [DOI:10.1038/s41576-022-00562-w] [PMID] [PMCID]
  54. Niture S, Lin M, Rios-Colon L, Qi Q, Moore JT, Kumar D. Emerging Roles of Impaired Autophagy in Fatty Liver Disease and Hepatocellular Carcinoma. Int J Hepatol. 2021;2021(1):6675762. [DOI:10.1155/2021/6675762] [PMID] [PMCID]
  55. Frassanito MA, De Veirman K, Desantis V, Di Marzo L, Vergara D, Ruggieri S, et al. Halting pro-survival autophagy by TGFbeta inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. Leukemia. 2016;30(3): 640-8. [DOI:10.1038/leu.2015.289] [PMID]
  56. Milan E, Perini T, Resnati M, Orfanelli U, Oliva L, Raimondi A, et al. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells. Autophagy. 2015;11(7):1161-78. [DOI:10.1080/15548627.2015.1052928] [PMID] [PMCID]
  57. Riz I, Hawley TS, Marsal JW, Hawley RG. Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming. Oncotarget. 2016;7(41):66360-85. [DOI:10.18632/oncotarget.11960] [PMID] [PMCID]
  58. Hu Y, Liu H, Fang C, Li C, Xhyliu F, Dysert H, et al. Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma. 2020;80(10):2031-44. [DOI:10.1158/0008-5472.CAN-19-1077] [PMID] [PMCID]
  59. Wang X, Lan Z, He J, Lai Q, Yao X, Li Q, et al. LncRNA SNHG6 promotes chemoresistance through ULK1-induced autophagy by sponging miR-26a-5p in colorectal cancer cells. 2019;19:1-12. [DOI:10.1186/s12935-019-0951-6] [PMID] [PMCID]
  60. Singh D, Assaraf YG, Gacche RN. Long non-coding RNA mediated drug resistance in breast cancer. Drug Resist Updat. 2022;63:100851. [DOI:10.1016/j.drup.2022.100851] [PMID]
  61. Hu Y, Lin J, Fang H, Fang J, Li C, Chen W, et al. Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma. Leukemia. 2018;32(10):2250-62. [DOI:10.1038/s41375-018-0104-2] [PMID] []
  62. Handa H, Kuroda Y, Kimura K, Masuda Y, Hattori H, Alkebsi L, et al. Long non‐coding RNA MALAT 1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma. 2017;179(3):449-60. [DOI:10.1111/bjh.14882] [PMID]
  63. Fu S, Wang Y, Li H, Chen L, Liu Q. Regulatory Networks of LncRNA MALAT-1 in Cancer. Cancer Manag Res. 2020;12:10181-98. [DOI:10.2147/CMAR.S276022] [PMID] [PMCID]
Iranian Journal of Pathology
Volume 19, Issue 4
Autumn 2024
Pages 422-430

  • Receive Date 15 February 2024
  • Revise Date 14 June 2024
  • Accept Date 14 July 2024

Home

Guide for Authors

Submit Manuscript

Contact Us